203
Participants
Start Date
July 31, 2008
Primary Completion Date
January 31, 2010
Study Completion Date
June 30, 2010
Infliximab
3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
Huntsville
Paradise Valley
Tucson
Santa Monica
Bridgeport
Lewes
Boca Raton
Palm Harbor
Tamarac
Vero Beach
Atlanta
Moline
Springfield
Lexington
Wheaton
Saint Clair Shores
Eagan
Springfield
St Louis
Berkeley Heights
Freehold
Albany
Syracuse
Chapel Hill
Columbus
Mayfield
Middleburg Heights
Tulsa
Allentown
Duncansville
Wexford
Charleston
Greenville
Jackson
Nashville
Amarillo
Dallas
Fort Worth
Houston
Mesquite
Temple
Tyler
Burke
Reston
Seattle
Graz-Eggenberg
Vienna
Vancouver
Winnipeg
St. John's
Toronto
Hamilton Ontario
Helsinki
Bordeaux
Limoges
Montivilliers
Orléans
Frankfurt
Holdenfelde
Leipzig
München
Ratingen
Ashkelon
Beer Yaakov
Haifa
Kfar Saba
Ramat Gan
Rehovot
Tel Aviv
Alkmaar
Madrid
Oviedo
Santiago de Compostela
Leeds
London
Wigan
Collaborators (1)
Schering-Plough
INDUSTRY
Centocor Ortho Biotech Services, L.L.C.
INDUSTRY